Hostname: page-component-586b7cd67f-rcrh6 Total loading time: 0 Render date: 2024-11-30T15:17:10.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Current Trends in Neuropathic Pain Treatments with Special Reference to Fibromyalgia

Published online by Cambridge University Press:  07 November 2014

Martin Offenbaecher  and
Manfred Ackenheil
Get access Rights & Permissions [Opens in a new window]

Abstract

Neuropathic pain and fibromyalgia are prevalent diseases which have major consequences on healthcare resources and the individual. From the clinical point of view neuropathic pains represent a heterogeneous group of aetiologically different diseases ranging from cancer to diabetes. Patients with fibromyalgia also display clinical features common in neuropathic pain suggesting that there might be some overlap. The mechanisms responsible for symptoms and signs in both diseases are still unknown. Recently, there have been numerous reports of various pharmacological treatments of neuropathic pain and fibromyalgia with often disappointing results. Most of the studies were of short duration, had high attrition rates, and displayed other methodological problems. Some compounds had high rates of adverse effects which makes it often difficult for the patients to tolerate the treatment, especially in the long-term. At present, the best options for medication treatment are tricyclic antidepressants in lower dosage than usual in psychiatric disorders and a wide range of anticonvulsants. Opioids are sometimes recommended but have been found to have minor efficacy. Recently, there have been more controlled trials, which are reported here if they had been published between 2002 and 2004. Various compounds have been tested in different studies. Treatment of fibromyalgia, which has many features in common with depressive symptoms, became the focus of interest. New promising studies with dual serotonin-norepinephrine reuptake inhibitors (duloxetine and milnacipram) and a newer antiepileptic drug (pregabalin) are in progress. Future research will have to apply new approaches (eg, using a mechanism based classification of neuropathic pain and carrying out studies in populations with the same symptom but not necessarily the same disease) in order to find effective treatments for these common and often debilitating diseases.

Type
Review Article
Information
CNS Spectrums , Volume 10 , Issue 4 , April 2005 , pp. 285 - 297
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.International Association for the Study of Pain web site. IASP pain terminology. Available at: http://www.iasp-pain.org/terms-p.html. Accessed on: July 26, 2004.Google Scholar
2.Jensen, TS, Gottrup, H, Sindrup, SH, Bach, FW. The clinical picture of neuropathic pain. Eur J Pharmacol. 2001;429:1–11.CrossRefGoogle ScholarPubMed
3.Carter, GT, Galer, BS. Advances in the management of neuropathic pain. Phys Med Rehabil Clin N Am. 2001;12:447–459.CrossRefGoogle ScholarPubMed
4.Smith, TE, Chong, MS. Neuropathic pain. Hosp Med. 2000;61:760–766.Google Scholar
5.Berger, A, Dukes, EM, Oster, G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain. 2004;5:143–149.Google Scholar
6.Haythornthwaite, JA, Benrud-Larson, LM. Psychological aspects of neuropathic pain. Clin J Pain. 2000;16(2 suppl):S101–S105.Google Scholar
7.Jensen, TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain. 2002;6(suppl A):61–68.CrossRefGoogle ScholarPubMed
8.Wall, PD. Neuropathic pain and injured nerve: central mechanisms. Br Med Bull. 1991;47:631–643.CrossRefGoogle ScholarPubMed
9.Otto, M, Bak, S, Bach, FW, Jensen, TS, Sindrup, SH. Pain phenomena and possible mechanisms in patients with painful polyneuropathy. Pain. 2003;101:187–192.Google Scholar
10.Woolf, CJ, Bennett, GJ, Doherty, M, et al.Towards a mechanism-based classification of pain? Pain. 1998;77:227–229.CrossRefGoogle ScholarPubMed
11.Jensen, TS, Baron, R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102:1–8.CrossRefGoogle ScholarPubMed
12.Woolf, CJ, Decosterd, I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain. 1999;6:S141–S147.CrossRefGoogle Scholar
13.Hansson, P. Difficulties in stratifying neuropathic pain by mechanisms. Eur J Pain. 2003;7:353–357.Google Scholar
14.Martinez-Lavin, M, Lopez, S, Medina, M, Nava, A. Use of the Leeds assessment of neuropathic symptoms and signs questionnaire in patients with fibromyalgia. Semin Arthritis Rheum. 2003;32:407–411.CrossRefGoogle ScholarPubMed
15.Staud, R, Domingo, M. Evidence for abnormal pain processing in fibromyalgia syndrome. Pain Med. 2001;2:208–215.CrossRefGoogle ScholarPubMed
16.Wolfe, F, Ross, K, Anderson, J, Russell, IJ, Hebert, L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19–28.CrossRefGoogle ScholarPubMed
17.Wolfe, F, Smythe, HA, Yunus, MB, et al.The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–172.Google Scholar
18.Offenbaecher, M, Bondy, B, de Jonge, S, et al.Possible association of fibromyalgia with a polymorphismus in the serotonin transporter gene regulatory region. Arthritis Rheum. 1999;42:2482–2488.3.0.CO;2-B>CrossRefGoogle Scholar
19.Cohen, H, Buskila, D, Neumann, L, Ebstein, RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5-HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum. 2002;46:845–847.Google Scholar
20.Kranzler, JD, Gendreau, JF, Rao, SG. The psychopharmacology of fibromyalgia: a drug development perspective. Psychopharmacol Bull. 2002;36:165–213.Google ScholarPubMed
21.Chong, MS, Baja, ZH. Diagnosis and treatment of neuropathic pain. J Pain Symptom Manage 2003;25(5 suppl):4–11.CrossRefGoogle ScholarPubMed
22.Barkhuizen, A. Rational and targeted pharmacologic treatment of fibromyalgia. Rheum Dis Clin North Am. 2002;28:261–290.CrossRefGoogle ScholarPubMed
23.Carette, S, McCain, GA, Bell, DA, Fam, AG. Evaluation of amitriptyline in primary fibrositis. A double blind placebo-controlled study. Arthritis Rheum. 1986;29:655–659.CrossRefGoogle ScholarPubMed
24.Scudds, RA, McCain, GA, Rollman, GB, Harth, M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. J Rheumatol Suppl. 1989:19:98–103.Google Scholar
25.Carette, S, Bell, MJ, Reynolds, WJ, et al.Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis Rheum. 1994;37:32–40.Google Scholar
26.Carette, S, Oakson, G, Guimont, C, Steriade, M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis Rheum. 1995;38:1211–1217.CrossRefGoogle ScholarPubMed
27.Ginsberg, F, Mancaux, A, Joos, E, Vanhove, P, Famaey, JP. A randomized placebo-controlled trial of sustained-release amitriptyline in primary fibromyalgia. J Musculoskeletal Pain. 1996;4:37–47.Google Scholar
28.Popoli, M, Gennarelli, M, Racagni, G. Modulation of synaptic plasticity by stress and antidepressants. Bipolar Disord. 2002;4:166–182.CrossRefGoogle ScholarPubMed
29.Pancrazio, JJ, Kamatchi, GL, Roscoe, AK, Lynch, C 3rd. Inhibition of neuronal Na+ channels by antidepressant drugs. J Pharmacol Exp Ther. 1998;284:208–214.Google Scholar
30.McQuay, H, Carroll, D, Jadad, AR, Wiffen, P, Moore, A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047–1052.Google Scholar
31.Kingery, WS. A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain. 1997;73:123–139.CrossRefGoogle ScholarPubMed
32.Sindrup, SH, Jensen, TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83:389–400.CrossRefGoogle ScholarPubMed
33.Sindrup, SH, Jensen, TS. Pharmacologic treatment of pain in polyneuropathy. Neurology. 2000;55:915–920.Google Scholar
34.Gimbel, JS, Richards, P, Portenoy, RK. Controlled release oxycodone for pain in diabetic neuropathy. A randomized controlled trial. Neurology. 2003;60:927–934.Google Scholar
35.Watson, CP, Moulin, D, Watt-Watson, J, Gordon, A, Eisenhoffer, J. Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain. 2003;105:71–78.Google Scholar
36.Attal, N, Guirimand, F, Brasseur, L, Gaude, V, Chauvin, M, Bouhassira, D. Effects of IV morphine in central pain: a randomized placebo-controlled study. Neurology. 2002;58:554–63.Google Scholar
37.Morley, JS, Bridson, J, Nash, TP, Miles, JB, White, S, Makin, MK. Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med. 2003;17:576–587.Google Scholar
38.Kalman, S, Österberg, A, Sörensen, J, Boivie, J, Bertler, A. Morphine responsiveness in a group of well-defined multiple sclerosis patients: a study with i.v. morp. Eur J Pain. 2002;6:69–80.Google Scholar
39.Rowbotham, MC, Twilling, L, Davies, PS, Reisner, L, Taylor, K, Mohr, D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348:1223–1232CrossRefGoogle ScholarPubMed
40.Rojas-Corrales, MO, Gibert-Rahola, J, Mico, JA. Tramadol induces antidepressanttype effects in mice. Life Sci. 1998;63:175–1s80.CrossRefGoogle ScholarPubMed
41.Rojas-Corrales, MO, Ortega-Alvaro, A, Gibert-Rahola, J, Roca-Vindardell, A, Mico, JA. Pindolol, a beta adrenoceptor blocker/5-hydroxytryptamine (1/1B) antagonist, enhances the analgesic effect of tramadol. Pain. 2000;88:119–124.CrossRefGoogle Scholar
42.Kvarnström, A, Karlsten, R, Qudiing, H, Emanuelsson, BM, Gordh, T. The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. Acta Anaesthesiol Scand. 2003;47:868–877.CrossRefGoogle ScholarPubMed
43.Jorum, E, Warncke, T, Stubhaug, A. Cold allodynia and hyperalgesia in neuropathic pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine–a double-blind, cross-over comparison with alfentanil and placebo. Pain. 2003;101:229–235.Google Scholar
44.Amin, P, Sturrock, NDC. A pilot study of the beneficial effects of amantadine in the treatment of painful diabetic peripheral neuropathy. Diabet Med. 2003;20:114–118.Google Scholar
45.Wallace, MS, Rowbotham, MC, Katz, NP, et al.A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain. Neurology. 2002;59:1694–1700.Google Scholar
46.Sang, CN, Booher, S, Gilron, I, Parada, S, Max, MB. Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and doseresponse trials. Anesthesiology. 2002;96:1053–1061.CrossRefGoogle ScholarPubMed
47.Carlsson, KC, Hoem, NO, Moberg, ER, Mathisen, LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 2004;48:328–336.Google Scholar
48.Simpson, DM, McArthur, JC, Olney, R, et al.Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. Neurology. 2003;60:1508–1514.Google Scholar
49.Finnerup, NB, Sindrup, SH, Bach, FW, Johannesen, IL, Jensen, TS. Lamotrigine in spinal cord injury pain: a randomized controlled trial. Pain. 2002;96:375–383.Google Scholar
50.Sabatowski, R, Galvez, R, Cherry, DA, et al.Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain. 2004;109:26–35.Google Scholar
51.Bone, M, Critchley, P, Buggy, DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over stduy. Reg Anesth Pain Med. 2002;27:481–486.Google Scholar
52.Serpell, MG; Neuropathic pain study group. Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial. Pain. 2002;99:557–566.Google Scholar
53.Caraceni, A, Zecca, E, Bonezzi, C, et al.Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909–2917.Google Scholar
54.Levendoglu, F, Ogun, CO, Ozerbil, O, Ogun, TC, Ugurlu, H. Gabapentin is a first line drug for the treatment of neuropathic pain in spinal cord injury. Spine. 2004;29:743–751.CrossRefGoogle ScholarPubMed
55.Thienel, U, Neto, W, Schwabe, SK, Vijapurkar, U; Topiramate Diabetic Neuropathic Pain Study Group. Topiramate in painful diabetic polyneuropathy: findings from three double-blind placebo-controlled trials. Acta Neurol Scand. 2004;110:221–231.Google Scholar
56.McCleane, GJ. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett. 2003;338:151–154.Google Scholar
57.Lynch, ME, Clark, AJ, Sawynok, J. Intravenous adenosine alleviates neuropathic pain: a double blind placebo controlled crossover trial using an enriched enrolment design. Pain. 2003;103:111–117.CrossRefGoogle ScholarPubMed
58.Eisenach, JC, Rauck, RL, Curry, R. Intrathecal, but not intravenous adenosine reduces allodynia in patients with neuropathic pain. Pain. 2003;105:65–70.CrossRefGoogle Scholar
59.Ametov, AS, Barinov, A, Dyck, PJ, et al.The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial. Diabetes Care. 2003;26:770–776.Google Scholar
60.Yuen, KCJ, Baker, NR, Rayman, G. Treatment of chronic painful diabetic neuropathy with isosorbide dinitrate spray. Diabetes Care. 2002;25:1699–1703.Google Scholar
61.Brill, S, Sedgwick, PM, Hamann, W, Di Vadi, PP. Efficacy of intravenous magnesium in neuropathic pain. Br J Anaesth. 2002;89:711–714.Google Scholar
62.Lynch, ME, Clark, AJ, Sawynok, J. A pilot study examining topical amitriptyline, ketamin, and a combination of both in the treatment of neuropathic pain. Clin J Pain. 2003;19:323–328.Google Scholar
63.Svendsen, KB, Jensen, TS, Bach, FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329:253.CrossRefGoogle ScholarPubMed
64.Meier, T, Wasner, G, Faust, M, et ak.Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151–158.CrossRefGoogle ScholarPubMed
65.Sharma, U, lacobellis, D, Glessner, C. Two studies show pregabalin effectively relieves pain in patients with painful diabetic peripheral neuropathy. Abstract presented at the Annual Meeting of the American Pain Society. November 2-5, 2000; Atlanta, GA.Google Scholar
66.Bryans, JS, Wustrow, DJ. 3-substituted GABA analogs with central nervous system activity: a review. Med Res Tev. 1999;19:149–177.Google Scholar
67.Kamata, M, takahashi, H, Sato, K, Naito, S, Higuchi, H. Efficacy of milnacipram for the treatment of chronic pain patients. Poster presented at: Annual meeting of the MYOPAIN congress. July 18-22, 2004; Munich, Germany.Google Scholar
68.Crofford, LJ, Rowbotham, MC, Mease, PJ, et al. Efficacy of pregabalin for treatment and associated symptoms in patients with fibromyalgia syndrome (FMS). Poster presented at: Annual meeting of the MYOPAIN congress. July 18-22, 2004; Munich, Germany.Google Scholar
69.Psychiatry Congress Reports page [Psychiatry Source web site]. Available at: http://www.actioncns.com/psychsource/Congress_Reports/Mood_Disorders/article638.htm. Accessed July 26, 2004.Google Scholar
70.Susman, E. IDF: Duloxetine Relieves Pain Associated With Diabetic Neuropathy [Doctor's Guide Global Edition Web site]. Available at: http://www.pslgroup.com/dg/2390F2.htm. Accessed July 26, 2004.Google Scholar
71.Bymaster, FP, Dreshfield-Ahmad, LJ, Threlkeld, PG, et al.Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporter in vitro, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology. 2001;25:871–880.Google Scholar
72.Goldstein, DJ, Lu, Y, Detke, MJ, Hudson, J, Iyengar, S, Demitrack, MA. Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics. 2004;45:17–28.CrossRefGoogle ScholarPubMed
73.Max, MB, Schafer, SC, Culnane, M, Dubner, R, Gracely, RH. Association of pain relief with drug side effects in postherpetic neuralgia: a single dose study of clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther. 1988;43:363–371.Google Scholar
74.Beydoun, A, Backonja, MM. Mechanistic stratification of antineuralgic agents. J Pain Symptom Manage. 2003;25:18–30.Google Scholar